Beta-Blocker Attenuates Cardiotoxicity Related Anthracycline Usage
Lukman Zulkifli Amin MD¹, Hilman Zulkifli Amin MD, PhD¹, Zulkifli Amin MD, PhD¹
Affiliation : ¹ Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia
To summarize the recent trials and studies of the role of beta-blocker on the treatment for cancer patients treated with anthracycline to decrease
morbidity and mortality rate. Good management of cancer will result in large numbers of cancer survivors. On the other hand, cancer therapy also
has side effects, one of which is cardiotoxicity. Cardiotoxicity could reduce therapy effectiveness, hence, increase disease progression and mortality
rate. Anthracyclines is one of the chemotherapy agents with cardiotoxicity as a side effect. Beta-blocker has the ability to reduce cardiotoxicity
due to anthracyclines usage.
Received 2 August 2018 | Revised 21 August 2019 | Accepted 23 April 2021
doi.org/10.35755/jmedassocthai.2021.08.9268
Keywords : Beta-blocker; Cardiotoxicity; Anthracyclines
